Cancer Research Targets  Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Medina, O. P.
Right arrow Articles by Kinnunen, P. K. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Medina, O. P.
Right arrow Articles by Kinnunen, P. K. J.
[Cancer Research 61, 3978-3985, May 15, 2001]
© 2001 American Association for Cancer Research


Experimental Therapeutics

Binding of Novel Peptide Inhibitors of Type IV Collagenases to Phospholipid Membranes and Use in Liposome Targeting to Tumor Cells in Vitro1

Oula Penate Medina, Tim Söderlund, Liisa J. Laakkonen, Esa K. J. Tuominen, Erkki Koivunen and Paavo K. J. Kinnunen2

Helsinki Biophysics and Biomembrane Group, Department of Medical Chemistry, Institute of Biomedicine [O. P. M., T. S., L. J. L., E. K. J. T., P. K. J. K.], and Department of Biosciences, Division of Biochemistry [E. K.], University of Helsinki, Helsinki, FIN-00014, Finland

We have recently described a novel cyclic peptide inhibitor CTTHWGFTLC (CTT) for matrix metalloproteinases (MMP)-2 and MMP-9, also called type IV collagenases or gelatinases (E. Koivunen et al., Nat. Biotechnol., 17: 768–774, 1999). As indicated by its amino acid composition, CTT is hydrophobic, and its partitioning into phospholipid films could be verified by the monolayer technique. Augmented fluorescence emission anisotropy (from 0.064 to 0.349) and reduced collisional quenching by I- of the Trp residue in CTT was evident in the presence of unilamellar phosphatidylcholine/phosphatidylethanolamine liposomes, revealing the association of CTT with the lipid bilayers. Gelatinases are potential targets of therapeutic intervention in cancer, and inhibitors of these enzymes can prevent tumor progression in animal models. CTT enhanced 3- to 4-fold the cellular uptake of liposome-encapsulated water-soluble fluorescent marker, rhodamine B by gelatinase-expressing cells. Gelatinase targeting seems to be essential, as modified peptides that were less potent gelatinase inhibitors were also less efficient in promoting the cellular uptake of liposomes. Augmented killing (~4-fold) of U937 leukemia and HT1080 sarcoma cells was obtained by the CTT-enhanced delivery of Adriamycin-containing liposomes, compared with control liposomes administered without the peptide. These results suggest a novel type of utility for small gelatinase inhibitors in targeted cancer therapy.




This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
H. W. van Deventer, Q. P. Wu, D. T. Bergstralh, B. K. Davis, B. P. O'Connor, J. P.-Y. Ting, and J. S. Serody
C-C Chemokine Receptor 5 on Pulmonary Fibrocytes Facilitates Migration and Promotes Metastasis via Matrix Metalloproteinase 9
Am. J. Pathol., July 1, 2008; 173(1): 253 - 264.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
C. A. Reichel, M. Rehberg, P. Bihari, C. M. Moser, S. Linder, A. Khandoga, and F. Krombach
Gelatinases mediate neutrophil recruitment in vivo: evidence for stimulus specificity and a critical role in collagen IV remodeling
J. Leukoc. Biol., April 1, 2008; 83(4): 864 - 874.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J.-o Deguchi, M. Aikawa, C.-H. Tung, E. Aikawa, D.-E. Kim, V. Ntziachristos, R. Weissleder, and P. Libby
Inflammation in Atherosclerosis: Visualizing Matrix Metalloproteinase Action in Macrophages In Vivo
Circulation, July 4, 2006; 114(1): 55 - 62.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
A. Khandoga, J. S. Kessler, M. Hanschen, A. G. Khandoga, D. Burggraf, C. Reichel, G. F. Hamann, G. Enders, and F. Krombach
Matrix metalloproteinase-9 promotes neutrophil and T cell recruitment and migration in the postischemic liver
J. Leukoc. Biol., June 1, 2006; 79(6): 1295 - 1305.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
R. Bucki, J. J. Pastore, P. Randhawa, R. Vegners, D. J. Weiner, and P. A. Janmey
Antibacterial Activities of Rhodamine B-Conjugated Gelsolin-Derived Peptides Compared to Those of the Antimicrobial Peptides Cathelicidin LL37, Magainin II, and Melittin
Antimicrob. Agents Chemother., May 1, 2004; 48(5): 1526 - 1533.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
X.-Q. Wang, P. Sun, and A. S. Paller
Ganglioside GM3 Inhibits Matrix Metalloproteinase-9 Activation and Disrupts Its Association with Integrin
J. Biol. Chem., July 3, 2003; 278(28): 25591 - 25599.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. C. Cunningham, R. Vegners, R. Bucki, M. Funaki, N. Korde, J. H. Hartwig, T. P. Stossel, and P. A. Janmey
Cell Permeant Polyphosphoinositide-binding Peptides That Block Cell Motility and Actin Assembly
J. Biol. Chem., November 9, 2001; 276(46): 43390 - 43399.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.